Scarica l'app Stockscreener
5.70
0.70%
-0.04
Dopo l'orario di chiusura:
5.64
-0.06
-1.05%
Precedente Chiudi:
$5.74
Aprire:
$5.79
Volume 24 ore:
73,569
Relative Volume:
0.85
Capitalizzazione di mercato:
$36.78M
Reddito:
$5.75M
Utile/perdita netta:
$-38.96M
Rapporto P/E:
-0.4571
EPS:
-12.47
Flusso di cassa netto:
$-32.63M
1 W Prestazione:
+0.00%
1M Prestazione:
+41.09%
6M Prestazione:
-25.78%
1 anno Prestazione:
-15.68%
Intervallo 1D:
$5.64
$5.9256
Intervallo di 1 settimana:
$5.39
$6.30
Portata 52W:
$2.92
$11.20
Kala Bio Inc Stock (KALA) Company Profile
Nome
Kala Bio Inc
Settore
Industria
Telefono
781-996-5252
Indirizzo
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Confronta KALA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
5.70 | 36.78M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-11 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-08-06 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-14 | Downgrade | Jefferies | Buy → Hold |
| 2020-07-23 | Iniziato | Northland Capital | Outperform |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-27 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-09 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-12-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-03-14 | Iniziato | Jefferies | Buy |
Mostra tutto
Kala Bio Inc Borsa (KALA) Ultime notizie
What analysts say about KALA BIO Inc. stockTriple-digit return opportunities - Autocar Professional
KALA BIO Inc. Stock Analysis and ForecastJaw-dropping returns - jammulinksnews.com
Is KALA BIO Inc. a good long term investmentUnmatched profit growth - Autocar Professional
KALA BIO (NASDAQ:KALA) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
What makes KALA BIO Inc. stock price move sharplyHigh Return Conservative Stocks - Newser
Why KALA BIO Inc. stock attracts strong analyst attentionMomentum Buy Alert - Newser
How KALA BIO Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - Newser
All Eyes On KALA's CHASEWill The PCED Trial Make Its Case? - RTTNews
LADENBURG THALM/SH SH Initiates Coverage on KALA BIO (NASDAQ:KALA) - Defense World
KALA Bio completes enrollment of CHASE clinical trial - Ophthalmology Times
KALA BIO (NASDAQ:KALA) Upgraded by Wall Street Zen to Hold Rating - Defense World
This Harrow Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Ladenburg Thalmann Initiates KALA BIO at Buy With $12 Price Target - MarketScreener
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg | KALA Stock News - GuruFocus
Kala Pharmaceuticals (KALA) Receives Buy Rating from Ladenburg - GuruFocus
Kala Bio Announces Completion of Enrollment in Chase Clinical Trial Evaluating Kpi-012 for the Treatment of Persistent Corneal Epithelial Defect - MarketScreener
KALA Completes Patient Enrollment in Phase 2b CHASE Trial for KP - GuruFocus
Kala Pharmaceuticals Completes Enrollment for Phase 2b Trial - TipRanks
Kala Bio completes enrollment in Phase 2b trial for KPI-012 in eye disorder - Investing.com
KALA BIO Completes Patient Enrollment in CHASE Phase 2b Trial for KPI-012, Anticipates Topline Results by Q3 2025 - Quiver Quantitative
KALA BIO Announces Completion of Enrollment in CHASE - GlobeNewswire
KALA BIO Eyes 100,000 Patient Market as Pivotal PCED Trial Completes Enrollment, Q3 Results Ahead - Stock Titan
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discu - GuruFocus
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to - GlobeNewswire
KALA BIO to Host Virtual Key Opinion Leader (KOL) Event to Discuss the Potential of KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) - Yahoo Finance
Millennium Management LLC Purchases 17,130 Shares of HBT Financial, Inc. (NASDAQ:HBT) - Defense World
Millennium Management LLC Decreases Stake in KALA BIO, Inc. (NASDAQ:KALA) - Defense World
Nexa Resources S.A. (NYSE:NEXA) Shares Sold by Millennium Management LLC - Defense World
24,353 Shares in T. Rowe Price Floating Rate ETF (NYSEARCA:TFLR) Acquired by Bank of America Corp DE - Defense World
Cadre Holdings, Inc. (NYSE:CDRE) Shares Acquired by Millennium Management LLC - Defense World
Bank of America Corp DE Acquires 2,612 Shares of First Trust Indxx Global Natural Resources Income ETF (NASDAQ:FTRI) - Defense World
Millennium Management LLC Sells 1,791 Shares of Bluerock Homes Trust, Inc. (NYSEAMERICAN:BHM) - Defense World
Ameriprise Financial Inc. Buys 11,012 Shares of Liberty All-Star Growth Fund, Inc. (NYSE:ASG) - Defense World
Kala Bio director Mark Iwicki sells $40,638 in stock By Investing.com - Investing.com South Africa
Kala Bio director Mark Iwicki sells $40,638 in stock - Investing.com India
KALA BIO Executives Sell Shares - TradingView
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
KALA BIO (NASDAQ:KALA) Given “Outperform” Rating at Oppenheimer - Defense World
KALA: Oppenheimer Announces Outperform Rating for Kala Bio | KALA Stock News - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | - GuruFocus
KALA Stock Gains Momentum with Oppenheimer's Positive Outlook | KALA Stock News - GuruFocus
Tidal Investments LLC Has $269,000 Stake in Air Lease Co. (NYSE:AL) - Defense World
Aegon Ltd. (NYSE:AEG) Shares Sold by Millennium Management LLC - Defense World
KALA BIO to Present at Jefferies Global Healthcare Conference - The Manila Times
KALA BIO to Reveal Latest Eye Disease Pipeline Progress at Major Jefferies Healthcare Conference - Stock Titan
Q1 Earnings Estimate for KALA BIO Issued By HC Wainwright - Defense World
HC Wainwright Lowers KALA BIO (NASDAQ:KALA) Price Target to $12.00 - Defense World
Kala Bio Inc Azioni (KALA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.87%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):